LUYAN PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 220 million yuan, a year-on-year decrease of 14.64%
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, LUYAN PHARMA released its third quarter report for 2025. In the first three quarters, the company achieved operating revenue of 15.855 billion yuan, a year-on-year increase of 2.87%. The net profit attributable to shareholders of the listed company was 220 million yuan, a year-on-year decrease of 14.64%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 220 million yuan, a year-on-year decrease of 15.14%
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments